Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in adult patients, targeting the BCR‑ABL protein that drives malignant cell growth.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted therapy used within the chronic myeloid leukemia treatment pathway.

- Chronic phase CML: improves survival and reduces disease progression when used as first‑line therapy. - Accelerated phase CML: provides disease control for patients who have progressed beyond chronic phase. - Blast phase CML: used in combination with other agents to achieve remission in advanced disease.

Nilotinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Rash: skin erythema or pruritus. - Headache: mild to moderate intensity. - Fatigue: generalized tiredness. - Myalgia: muscle aches.

Serious or Rare Side Effects: - QT prolongation: risk of cardiac arrhythmia. - Pancreatitis: severe abdominal pain with elevated enzymes. - Hepatic injury: marked elevation of liver transaminases. - Severe neutropenia: increased infection risk. - Severe thrombocytopenia: bleeding tendency. - Anaphylactic reactions: rare but potentially life‑threatening.

Before initiating therapy, clinicians should assess several safety parameters.

- Cardiac monitoring: obtain baseline ECG and repeat periodically to detect QT prolongation. - Hepatic function: check liver enzymes before and during treatment. - Pancreatic enzymes: monitor amylase and lipase levels regularly. - Hematologic surveillance: perform complete blood counts to detect neutropenia or thrombocytopenia. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors and QT‑prolonging agents. - Pregnancy: contraindicated; classified as Category D, advise effective contraception. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nilotinib interacts with several medicines that can alter its plasma concentration or cardiac safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nilotinib exposure and toxicity. - QT‑prolonging agents (e.g., amiodarone, sotalol): additive risk of arrhythmia. - Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may modestly raise levels. - CYP3A4 inducers (e.g., St. John’s wort, rifampin): may lower efficacy. - Warfarin: monitor INR as nilotinib can affect anticoagulation control.